Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma (OPTIMUM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00452569
Recruitment Status : Completed
First Posted : March 27, 2007
Last Update Posted : November 23, 2016
Information provided by (Responsible Party):
Celgene Corporation